ProShare Advisors’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $853K | Sell |
17,927
-2,520
| -12% | -$133K | ﹤0.01% | 836 |
|
|
2025
Q4 | $1.07M | Buy |
20,447
+2,594
| +15% | +$155K | ﹤0.01% | 804 |
|
|
2025
Q3 | $1.16M | Sell |
17,853
-2,879
| -14% | -$165K | ﹤0.01% | 768 |
|
|
2025
Q2 | $1.01M | Buy |
+20,732
| New | +$802K | ﹤0.01% | 816 |
|
|
2024
Q4 | – | Sell |
-5,358
| Closed | -$252K | – | 2280 |
|
|
2024
Q3 | $252K | Sell |
5,358
-210
| -4% | -$10.7K | ﹤0.01% | 1581 |
|
|
2024
Q2 | $301K | Sell |
5,568
-223
| -4% | -$12.9K | ﹤0.01% | 1288 |
|
|
2024
Q1 | $395K | Buy |
5,791
+530
| +10% | +$37.9K | ﹤0.01% | 1239 |
|
|
2023
Q4 | $329K | Sell |
5,261
-62
| -1% | -$3.43K | ﹤0.01% | 1305 |
|
|
2023
Q3 | $242K | Buy |
5,323
+69
| +1% | +$3.56K | ﹤0.01% | 1345 |
|
|
2023
Q2 | $295K | Sell |
5,254
-556
| -10% | -$31.5K | ﹤0.01% | 1280 |
|
|
2023
Q1 | $263K | Sell |
5,810
-1,853
| -24% | -$90K | ﹤0.01% | 1282 |
|
|
2022
Q4 | $312K | Sell |
7,663
-141
| -2% | -$7.48K | ﹤0.01% | 1220 |
|
|
2022
Q3 | $510K | Buy |
7,804
+610
| +8% | +$44.2K | ﹤0.01% | 893 |
|
|
2022
Q2 | $437K | Sell |
7,194
-2,391
| -25% | -$141K | ﹤0.01% | 995 |
|
|
2022
Q1 | $602K | Sell |
9,585
-1,191
| -11% | -$74.8K | ﹤0.01% | 1167 |
|
|
2021
Q4 | $817K | Sell |
10,776
-5,502
| -34% | -$481K | ﹤0.01% | 1153 |
|
|
2021
Q3 | $1.82M | Buy |
16,278
+2,664
| +20% | +$335K | 0.01% | 734 |
|
|
2021
Q2 | $2.2M | Buy |
13,614
+3,194
| +31% | +$388K | 0.01% | 710 |
|
|
2021
Q1 | $1.27M | Sell |
10,420
-483
| -4% | -$72.9K | ﹤0.01% | 864 |
|
|
2020
Q4 | $1.67M | Sell |
10,903
-405
| -4% | -$47.9K | 0.01% | 691 |
|
|
2020
Q3 | $946K | Buy |
11,308
+1,557
| +16% | +$138K | ﹤0.01% | 737 |
|
|
2020
Q2 | $717K | Buy |
9,751
+1,556
| +19% | +$91K | ﹤0.01% | 801 |
|
|
2020
Q1 | $348K | Sell |
8,195
-4,661
| -36% | -$241K | ﹤0.01% | 832 |
|
|
2019
Q4 | $783K | Sell |
12,856
-1,941
| -13% | -$106K | ﹤0.01% | 885 |
|
|
2019
Q3 | $607K | Sell |
14,797
-645
| -4% | -$30.8K | ﹤0.01% | 913 |
|
|
2019
Q2 | $727K | Sell |
15,442
-2,318
| -13% | -$92.6K | ﹤0.01% | 880 |
|
|
2019
Q1 | $634K | Buy |
17,760
+95
| +0.5% | +$3.29K | ﹤0.01% | 938 |
|
|
2018
Q4 | $505K | Sell |
17,665
-1,739
| -9% | -$60.5K | ﹤0.01% | 946 |
|
|
2018
Q3 | $861K | Sell |
19,404
-426
| -2% | -$22.3K | 0.01% | 885 |
|
|
2018
Q2 | $1.17M | Sell |
19,830
-1,447
| -7% | -$82.4K | 0.01% | 776 |
|
|
2018
Q1 | $973K | Sell |
21,277
-823
| -4% | -$34K | 0.01% | 831 |
|
|
2017
Q4 | $519K | Buy |
+22,100
| New | +$420K | ﹤0.01% | 1113 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
ProShare Advisors's CRSP Position: Q1 2026 in Review
ProShare Advisors reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q1 2026, selling an estimated $133K and leaving 17,927 shares worth $853K. The position accounts for ﹤0.01% of the portfolio, ranked #836.
ProShare Advisors first reported a position in CRSP in Q4 2017 and has held it in 32 quarters since. The position peaked at $2.2M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- ProShare Advisors held 17,927 shares of CRISPR Therapeutics worth $853K as of Q1 2026.
- ProShare Advisors sold 2,520 CRISPR Therapeutics shares in Q1 2026, an estimated $133K.
- CRISPR Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #836 holding.
- ProShare Advisors first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 32 quarters since.
- ProShare Advisors's CRISPR Therapeutics position peaked at $2.2M in Q2 2021.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.